Yang Cuiping, Wu Wei, Yang Yanping, Yang Xiaojin, Sun Jing, Zhang Weiyu, Liu Kun, Ying Haifeng, Jiang Songyao, Yu Xiaojun, Shi Yiqing, Zhou Yufen, Zhu Shiyan, Xu Ying, Ding Yanfei, Xie Ling, Cai Boer, Xin Xiaorong, Chen Ping, Zhao Ren, Wu Yunlin
Department of Gastroenterology, Shanghai Jiao Tong University, School of Medicine, Ruijin Hospital North, Shanghai 201800, P.R. China.
Department of Gastroenterology, Shanghai Jiao Tong University, School of Medicine, Ruijin Hospital, Shanghai 200025, P.R. China.
Oncol Lett. 2020 Aug;20(2):1193-1200. doi: 10.3892/ol.2020.11674. Epub 2020 May 25.
Patient screening is important for early diagnosis of colorectal cancer (CRC). The present study aimed to compare the multitarget stool DNA (mt-sDNA) test with the fecal occult blood test (FOBT) for CRC screening. A total of 151 individuals were screened using colonoscopy, mt-sDNA and FOBT for the detection of CRC and adenoma. The results of the mt-sDNA test and FOBT were compared with colonoscopy to examine their sensitivity and specificity. Subsequently, the sensitivity and specificity of the mt-sDNA test were compared with those of FOBT in CRC and large adenoma. Stool samples were collected from patients with CRC (n=50) or large adenoma (n=51), as well as from normal controls (n=50). The mt-sDNA test outperformed FOBT in detecting CRC with a sensitivity of 90.0% (45/50) vs. 42.0% (21/50), advanced adenoma with a sensitivity of 70.6% (36/51) vs. 19.6% (10/51), stage I-III CRC with a sensitivity of 91.9% (34/37) vs. 29.7% (11/37), and stage IV CRC with a sensitivity of 84.6% (11/13) vs. 76.9% (10/13). In addition, the mt-sDNA test exhibited a specificity of 94.0% (47/50) in detecting CRC, which was superior to FOBT with a specificity of 90.0% (45/50). Therefore, the mt-sDNA test may have higher sensitivity and specificity compared with FOBT in diagnosing both CRC and advanced adenoma.
患者筛查对于结直肠癌（CRC）的早期诊断至关重要。本研究旨在比较多靶点粪便DNA（mt-sDNA）检测与粪便潜血试验（FOBT）用于CRC筛查的效果。共有151名个体接受了结肠镜检查、mt-sDNA检测和FOBT以检测CRC和腺瘤。将mt-sDNA检测和FOBT的结果与结肠镜检查结果进行比较，以评估它们的敏感性和特异性。随后，比较了mt-sDNA检测与FOBT在CRC和大腺瘤中的敏感性和特异性。从CRC患者（n = 50）或大腺瘤患者（n = 51）以及正常对照者（n = 50）中收集粪便样本。mt-sDNA检测在检测CRC方面优于FOBT，敏感性分别为90.0%（45/50）和42.0%（21/50）；在检测进展性腺瘤方面，敏感性分别为70.6%（36/51）和19.6%（10/51）；在检测I-III期CRC方面，敏感性分别为91.9%（34/37）和29.7%（11/37）；在检测IV期CRC方面，敏感性分别为84.6%（11/13）和76.9%（10/13）。此外，mt-sDNA检测在检测CRC时的特异性为94.0%（47/50），优于FOBT的特异性90.0%（45/50）。因此，与FOBT相比，mt-sDNA检测在诊断CRC和进展性腺瘤方面可能具有更高的敏感性和特异性。
